scholarly journals Prognostic value of tumor length and diameter for esophageal squamous cell cancer patients treated with definitive (chemo)radiotherapy: Potential indicators for nonsurgical T staging

2019 ◽  
Vol 8 (14) ◽  
pp. 6326-6334
Author(s):  
Hongyao Xu ◽  
Shengxi Wu ◽  
Hesan Luo ◽  
Chuyun Chen ◽  
Lianxing Lin ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Prognostic Value ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Tumor Length

scholarly journals Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Chieh Ho ◽  
Yuan-Chun Lai ◽  
Hsuan-Yu Lin ◽  
Ming-Hui Ko ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Performance Status ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Lymphocyte Ratio ◽  
Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Risk Patterns of Subsequent Primary Cancers following Esophagectomy in Early-Stage Thoracic Esophageal Squamous Cell Cancer Patients

2015 ◽  
Vol 101 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Wen-Si Hu ◽  
Zeng-Jun Liu ◽  
Jian-Bo Zhang ◽  
Zeng-Liang Wang ◽  
Ning Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer

scholarly journals Implications for the Ajcc Staging Systems on Esophageal Squamous Cell Cancer Patients Receiving Multimodality Therapy

2014 ◽  
Vol 25 ◽  
pp. v63
Author(s):  
Motoo Nomura ◽  
Tetsuya Abe ◽  
Hiroya Taniguchi ◽  
Shigenori Kadowaki ◽  
Daisuke Takahari ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Multimodality Therapy ◽  
Esophageal Squamous Cell Cancer ◽  
Staging Systems ◽  
Ajcc Staging

scholarly journals Microvessel density as a prognostic factor in esophageal squamous cell cancer patients

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7600 ◽  
Author(s):  
Guangzhi Ma ◽  
Jing Zhang ◽  
Hai Jiang ◽  
Nannan Zhang ◽  
Yunjie Zhu ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Microvessel Density ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document